StocksMedium•1 October 2026•
1 min read
Candel Therapeutics Reports Positive Phase 2a Lung Cancer Trial Results
Key Facts
1Candel Therapeutics announced positive Phase 2a clinical trial results for aglatimagene besadenovec in patients with stage III/IV NSCLC.
2The trial demonstrated a median overall survival of 24.5 months, exceeding historical benchmarks for standard-of-care chemotherapy.
Candel Therapeutics announced positive Phase 2a clinical trial results for aglatimagene besadenovec in patients with stage III/IV non-small cell lung cancer (NSCLC). According to a company statement reported via GlobeNewswire, the trial demonstrated a median overall survival of 24.5 months, exceeding historical benchmarks for standard-of-care chemotherapy.
The data validates the company's multimodal immunotherapy approach for patients who previously failed to respond to immune checkpoint inhibitors. In the equity markets, CADL closed at $10.44 on September 30, 2026, having traded between a session low of $10.37 and a high of $11.25.